NCT06311227 2026-03-18
Venetoclax for the Treatment of Patients With Relapsed Hairy Cell Leukemia
National Cancer Institute (NCI)
Phase 2 Recruiting
Clinical Trials
9 trialsNCT06317662 2026-03-18
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT07069699 2026-03-18
Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene
National Cancer Institute (NCI)
Phase 1/2 Recruiting
NCT05453500 2026-03-13
Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia
University of Washington
Phase 2 Recruiting
NCT06784726 2026-03-13
Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T
University of Washington
Phase 2 Recruiting
NCT06322602 2026-03-03
Ommaya Reservoir Placement at the Time of Biopsy for Longitudinal Biomarker Collection in Patients With Brain Tumors
Mayo Clinic
Phase NA Recruiting
NCT06247787 2026-02-24
A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy
Children's Oncology Group
Phase 1 Recruiting
NCT06368817 2026-02-24
A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma
Children's Oncology Group
Phase 2 Recruiting
NCT02981628 2026-02-23
Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
Children's Oncology Group
Phase 2 Recruiting